Resveratrol-Mediated Repression and Reversion of Prostatic Myofibroblast Phenoconversion

Area of Science:

• Biochemistry
• Cell Biology
• Urology

Background:

• Resveratrol, a natural compound, exhibits anti-inflammatory and anti-oxidative properties.
• Increased collagen deposition in the prostate is linked to lower urinary tract dysfunction (LUTD).

Purpose of the Study:

• To investigate Resveratrol's potential to inhibit or reverse prostate fibroblast to myofibroblast phenoconversion.
• To assess the efficacy of anti-fibrotic therapeutics for LUTD treatment.

Main Methods:

• Primary prostate and lung fibroblasts were cultured in vitro.
• Cells were treated with TGFβ or CXCL12, with or without Resveratrol.
• Evaluated myofibroblast markers (αSMA, COL1), proliferation, apoptosis, and gene expression.

Main Results:

• Low concentrations of Resveratrol repressed and reversed prostate fibroblast to myofibroblast phenoconversion.
• Resveratrol did not affect prostate fibroblast proliferation, apoptosis, or gene transcription.
• Similar effects were observed in idiopathic pulmonary fibrosis (IPF) lung fibroblasts, requiring higher Resveratrol concentrations.

Conclusions:

• Resveratrol treatment can both repress and reverse prostate fibroblast to myofibroblast phenoconversion.
• These findings support the potential efficacy of anti-fibrotic therapeutics for treating LUTD.